Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXGNNYSE:BVSNASDAQ:EMBCNASDAQ:RCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$9.75$13.40$6.59▼$21.00$444.05M1.05568,550 shs467,667 shsBVSBioventus$6.60-0.3%$7.03$5.28▼$14.38$542.15M0.86454,379 shs209,232 shsEMBCEmbecta$10.04+5.0%$11.45$9.49▼$21.48$586.77M1.13482,163 shs684,962 shsRCELAVITA Medical$5.47-1.3%$7.69$5.31▼$14.16$144.60M1.55184,052 shs152,970 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen0.00%-10.71%-17.58%-46.66%+27.62%BVSBioventus0.00%-1.05%-2.50%-32.45%+3.76%EMBCEmbecta0.00%-2.35%-20.47%-29.86%-25.31%RCELAVITA Medical0.00%-9.33%-14.24%-38.65%-33.81%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXGNAxoGen2.6687 of 5 stars3.52.00.00.02.72.50.6BVSBioventus3.0647 of 5 stars3.30.00.00.01.64.21.3EMBCEmbecta4.2596 of 5 stars3.21.03.30.01.43.33.8RCELAVITA Medical1.5063 of 5 stars3.40.00.00.03.40.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXGNAxoGen 3.00Buy$22.20127.69% UpsideBVSBioventus 2.67Moderate Buy$14.33117.17% UpsideEMBCEmbecta 2.33Hold$19.3392.56% UpsideRCELAVITA Medical 2.75Moderate Buy$16.50201.65% UpsideCurrent Analyst Ratings BreakdownLatest RCEL, AXGN, EMBC, and BVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/6/2025RCELAVITA MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.005/23/2025EMBCEmbectaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$25.005/23/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.005/13/2025AXGNAxoGenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $24.005/7/2025BVSBioventusCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$15.004/10/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$15.004/10/2025RCELAVITA MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.004/9/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold4/4/2025RCELAVITA MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/18/2025RCELAVITA MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/17/2025AXGNAxoGenLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXGNAxoGen$194.52M2.28N/AN/A$2.22 per share4.39BVSBioventus$567.70M0.95$0.52 per share12.58$2.80 per share2.36EMBCEmbecta$1.08B0.54$2.32 per share4.32($13.23) per share-0.76RCELAVITA Medical$71.66M2.02N/AN/A$0.17 per share32.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXGNAxoGen-$21.72M-$0.15N/AN/AN/A-7.91%-14.91%-7.49%8/14/2025 (Estimated)BVSBioventus-$156.23M-$0.48N/A14.35N/A-7.11%15.61%4.01%N/AEMBCEmbecta$78.30M$0.9010.043.270.785.25%-19.22%11.92%8/8/2025 (Estimated)RCELAVITA Medical-$61.85M-$2.19N/AN/AN/A-96.26%-337.91%-71.50%8/6/2025 (Estimated)Latest RCEL, AXGN, EMBC, and BVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q2 2025EMBCEmbecta$0.66$0.70+$0.04$0.40$261.77 million$259.00 million5/8/2025Q1 2025RCELAVITA Medical-$0.39-$0.53-$0.14-$0.53$33.15 million$18.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXGNAxoGenN/AN/AN/AN/AN/ABVSBioventusN/AN/AN/AN/AN/AEMBCEmbecta$0.605.98%N/A66.67%N/ARCELAVITA MedicalN/AN/AN/AN/AN/ALatest RCEL, AXGN, EMBC, and BVS DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/5/2025EMBCEmbectaquarterly$0.154.51%5/28/20255/28/20256/13/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXGNAxoGen0.673.742.47BVSBioventus1.851.410.99EMBCEmbectaN/A2.241.67RCELAVITA Medical9.392.832.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXGNAxoGen80.29%BVSBioventus62.94%EMBCEmbecta93.83%RCELAVITA Medical27.66%Insider OwnershipCompanyInsider OwnershipAXGNAxoGen2.78%BVSBioventus33.00%EMBCEmbecta0.42%RCELAVITA Medical2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXGNAxoGen45045.54 million40.93 millionOptionableBVSBioventus1,20082.14 million54.46 millionNot OptionableEMBCEmbecta1,90058.44 million57.89 millionOptionableRCELAVITA Medical13026.44 million25.74 millionOptionableRCEL, AXGN, EMBC, and BVS HeadlinesRecent News About These CompaniesReviewing Beyond Air (NASDAQ:XAIR) and AVITA Medical (NASDAQ:RCEL)June 15 at 1:19 AM | americanbankingnews.comCantor Fitzgerald Comments on AVITA Medical FY2026 EarningsJune 12, 2025 | americanbankingnews.comCantor Fitzgerald Predicts AVITA Medical FY2026 EarningsJune 11, 2025 | marketbeat.comAVITA Medical (NASDAQ:RCEL) Given Buy Rating at D. Boral CapitalJune 6, 2025 | marketbeat.comAVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™June 5, 2025 | finance.yahoo.comAVITA Medical's RECELL Platform Recognized for Surgical Innovation in 2025 MedTech Breakthrough AwardsJune 3, 2025 | globenewswire.comShort Interest in AVITA Medical, Inc. (NASDAQ:RCEL) Rises By 23.9%June 3, 2025 | marketbeat.comDelta Investment Management LLC Increases Holdings in AVITA Medical, Inc. (NASDAQ:RCEL)May 22, 2025 | marketbeat.comCantor Fitzgerald Comments on AVITA Medical FY2025 EarningsMay 16, 2025 | marketbeat.comAVITA Medical’s Acute Wound Care Showcase 2025 Streams Live TodayMay 13, 2025 | finance.yahoo.comAVITA Medical: Near-Perfect Execution Needed To Navigate Through Balance Sheet ChallengesMay 12, 2025 | seekingalpha.comAnalysts Have Been Trimming Their AVITA Medical, Inc. (NASDAQ:RCEL) Price Target After Its Latest ReportMay 11, 2025 | finance.yahoo.comAVITA Medical, Inc. (RCEL) Q1 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comAVITA Medical Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comAVITA Medical to Announce First Quarter 2025 Financial ResultsApril 17, 2025 | globenewswire.comAVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025April 9, 2025 | globenewswire.com6 Analysts Assess AVITA Medical: What You Need To KnowApril 6, 2025 | nasdaq.comAvita Medical announces U.S. commercial launch of CohealyxApril 4, 2025 | msn.comAVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market OpportunityApril 3, 2025 | globenewswire.comAVITA Medical’s SWOT analysis: regenerative medicine stock faces growth hurdlesMarch 21, 2025 | uk.investing.com4RCEL : What Analysts Are Saying About AVITA Medical StockMarch 18, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRCEL, AXGN, EMBC, and BVS Company DescriptionsAxoGen NASDAQ:AXGN$9.75 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$9.80 +0.05 (+0.51%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.Bioventus NYSE:BVS$6.60 -0.02 (-0.30%) Closing price 04:00 PM EasternExtended Trading$6.60 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.Embecta NASDAQ:EMBC$10.04 +0.48 (+5.02%) Closing price 04:00 PM EasternExtended Trading$10.04 0.00 (0.00%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.AVITA Medical NASDAQ:RCEL$5.47 -0.07 (-1.26%) Closing price 04:00 PM EasternExtended Trading$5.46 -0.01 (-0.18%) As of 04:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore SoundHound’s AI Growth Story Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
